Search Results - "Akhurst, Timothy J."

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update by Wong, Sandra L, Faries, Mark B, Kennedy, Erin B, Agarwala, Sanjiv S, Akhurst, Timothy J, Ariyan, Charlotte, Balch, Charles M, Berman, Barry S, Cochran, Alistair, Delman, Keith A, Gorman, Mark, Kirkwood, John M, Moncrieff, Marc D, Zager, Jonathan S, Lyman, Gary H

“…Purpose To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in…”
Get full text

Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline by WONG, Sandra L, BALCH, Charles M, DIRK NOYES, R, SCHUCHTER, Lynn M, VALSECCHI, Matias E, WEAVER, Donald L, LYMAN, Gary H, HURLEY, Patricia, AGARWALA, Sanjiv S, AKHURST, Timothy J, COCHRAN, Alistair, CORMIER, Janice N, GORMAN, Mark, KIM, Theodore Y, MCMASTERS, Kelly M

“…The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) sought to provide an evidence-based guideline on the use of lymphatic…”
Get full text

Sentinel Lymph Node Biopsy for Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Joint Clinical Practice Guideline by Wong, Sandra L., Balch, Charles M., Hurley, Patricia, Agarwala, Sanjiv S., Akhurst, Timothy J., Cochran, Alistair, Cormier, Janice N., Gorman, Mark, Kim, Theodore Y., McMasters, Kelly M., Noyes, R. Dirk, Schuchter, Lynn M., Valsecchi, Matias E., Weaver, Donald L., Lyman, Gary H.

“…Purpose The American Society of Clinical Oncology (ASCO) and Society of Surgical Oncology (SSO) sought to provide an evidence-based guideline on the use of…”
Get full text

Relative Value of Restaging MRI, CT, and FDG-PET Scan After Preoperative Chemoradiation for Rectal Cancer by Schneider, Daniel A, Akhurst, Timothy J, Ngan, Samuel Y, Warrier, Satish K, Michael, Michael, Lynch, Andrew C, Te Marvelde, Luc, Heriot, Alexander G

“…BACKGROUND:Management of rectal cancer has become multidisciplinary and is driven by the stage of the disease, with increased focus on restaging rectal cancer…”
Get full text

Sentinel Lymph Node Biopsy and Management of Regional Lymph Nodes in Melanoma: American Society of Clinical Oncology and Society of Surgical Oncology Clinical Practice Guideline Update by Wong, Sandra L., Faries, Mark B., Kennedy, Erin B., Agarwala, Sanjiv S., Akhurst, Timothy J., Ariyan, Charlotte, Balch, Charles M., Berman, Barry S., Cochran, Alistair, Delman, Keith A., Gorman, Mark, Kirkwood, John M., Moncrieff, Marc D., Zager, Jonathan S., Lyman, Gary H.

“…Purpose To update the American Society of Clinical Oncology (ASCO)-Society of Surgical Oncology (SSO) guideline for sentinel lymph node (SLN) biopsy in…”
Get full text

Propofol and thiopental do not interfere with regional cerebral blood flow response at sedative concentrations by VESELIS, Robert A, FESHCHENKO, Vladimir A, REINSEL, Ruth A, BEATTIE, Bradley, AKHURST, Timothy J

“…Anesthetics may affect the regional cerebral blood flow (rCBF) response associated with increased brain activity in humans. rCBF was measured as auditory…”
Get full text

Evaluation of 18F-FDG-PET for Early Detection of Suboptimal Response of Rectal Cancer to Preoperative Chemoradiotherapy: A Prospective Analysis by Leibold, Tobias, Akhurst, Timothy J., Chessin, David B., Yeung, Henry W., Macapinlac, Homer, Shia, Jinru, Minsky, Bruce D., Saltz, Leonard B., Riedel, Elyn, Mazumdar, Madhu, Paty, Philip B., Weiser, Martin R., Wong, W. Douglas, Larson, Steven M., Guillem, José G.

“…Background Early identification of inadequate response to preoperative chemoradiotherapy (CRT) may spare rectal cancer patients the toxicity of ineffective…”
Get full text

Feasibility of ex vivo FDG PET of the colon by Gollub, Marc J, Akhurst, Timothy J, Williamson, Matthew J, Shia, Jinru, Humm, John L, Wong, W Douglas, Paty, Philip B, Guillem, Jose G, Weiser, Martin R, Temple, Larissa K F, Dauer, Lawrence T, Jhanwar, Suresh C, Kronman, Rachel E, Montalvo, Carolina V, Miller, Allison R, Larson, Steven M, Margulis, Alexander R

“…To facilitate future direct correlations between fluorine 18 fluorodeoxyglucose (FDG)-avid colonic lesions and immunohistochemical assay findings, the authors…”
Get full text

Neither FDG-PET Nor CT Can Distinguish Between a Pathological Complete Response and an Incomplete Response After Neoadjuvant Chemoradiation in Locally Advanced Rectal Cancer: A Prospective Study by Guillem, José G, Ruby, Jeannine A, Leibold, Tobias, Akhurst, Timothy J, Yeung, Henry W, Gollub, Marc J, Ginsberg, Michelle S, Shia, Jinru, Suriawinata, Arief A, Riedel, Elyn R, Mazumdar, Madhu, Saltz, Leonard B, Minsky, Bruce D, Nash, Garrett M, Paty, Philip B, Temple, Larissa K, Weiser, Martin R, Larson, Steven M

“…OBJECTIVE:To prospectively compare the ability of flourodeoxyglucose-positron emission tomography (FDG-PET) and computed tomography (CT) to identify a…”
Get full text

A focal lesion in the falx cerebri: Harbinger of classic stage 4 neuroblastoma in an infant cured despite residual disease after minimal therapy by Kushner, Brian H., Kramer, Kim, Modak, Shakeel, Akhurst, Timothy J., Cheung, Nai-Kong V.

“…An asymptomatic 11 weeks old received no treatment after he was classified as having a suspected atypical form of MYCN‐nonamplified hyperdiploid stage 4S…”
Get full text

Predictive value of initial PET-SUVmax in patients with locally advanced esophageal and gastroesophageal junction adenocarcinoma by Rizk, Nabil P, Tang, Laura, Adusumilli, Prasad S, Bains, Manjit S, Akhurst, Timothy J, Ilson, David, Goodman, Karyn, Rusch, Valerie W

“…We have previously shown that in early clinical stage esophageal adenocarcinoma, a positron emission tomography standardized uptake values (PET SUVmax) of <4.5…”
Get more information

FDG-PET Assessment of Rectal Cancer Response to Neoadjuvant Chemoradiotherapy Is Not Associated With Long-Term Prognosis: A Prospective Evaluation by Ruby, Jeannine A, Leibold, Tobias, Akhurst, Timothy J, Shia, Jinru, Saltz, Leonard B, Mazumdar, Madhu, Riedel, Elyn R, Larson, Steven M, Guillem, José G

“…BACKGROUND:At present there is no defined role for routine FDG-PET in the preoperative evaluation of nonmetastatic rectal cancer. OBJECTIVE:The primary…”
Get full text

Thiopental and propofol affect different regions of the brain at similar pharmacologic effects by VESELIS, Robert A, FESHCHENKO, Vladimir A, REINSEL, Ruth A, DNISTRIAN, Ann M, BEATTIE, Bradley, AKHURST, Timothy J

“…Propofol has a greater amnesic effect than thiopental. In this study we tested whether different brain regions were affected by propofol and thiopental at…”
Get full text

Pilot study of 68Ga-DOTA-F(ab′)2-trastuzumab in patients with breast cancer by Beylergil, Volkan, Morris, Patrick G, Smith-Jones, Peter M, Modi, Shanu, Solit, David, Hudis, Clifford A, Lu, Yang, O’Donoghue, Joseph, Lyashchenko, Serge K, Carrasquillo, Jorge A, Larson, Steven M, Akhurst, Timothy J

“…OBJECTIVEGa-1,4,7,10-Tetraazacyclododecane-N,N′,N′′,N′′′-tetraacetic acid (DOTA)-F(ab′)2-trastuzumab [Ga-DOTA-F(ab′)2-trastuzumab] has been developed at our…”
Get full text

Feasibility of ex Vivo FDG PET of the Colon1 by GOLLUB, Marc J, AKHURST, Timothy J, DAUER, Lawrence T, JHANWAR, Suresh C, KRONMAN, Rachel E, MONTALVO, CarolinaV, MILLER, Allison R, LARSON, Steven M, MARGULIS, Alexander R, WILLIAMSON, MatthewJ, SHIA, Jinru, HUMM, John L, WONG, W. Douglas, PATY, Philip B, GUILLEM, Jose G, WEISER, Martin R, TEMPLE, Larissa K. F

“…To facilitate future direct correlations between fluorine 18 fluorodeoxyglucose (FDG)-avid colonic lesions and immunohistochemical assay findings, the authors…”
Get full text

Objective PET lesion segmentation using a spherical mean shift algorithm by Sebastian, Thomas B, Manjeshwar, Ravindra M, Akhurst, Timothy J, Miller, James V

“…PET imagery is a valuable oncology tool for characterizing lesions and assessing lesion response to therapy. These assessments require accurate delineation of…”
Get more information

Use of positron emission tomography to target prostate cancer gene therapy by oncolytic herpes simplex virus by Mullerad, Michael, Eisenberg, David P, Akhurst, Timothy J, Adusumilli, Prasad S, Riedl, Christopher C, Bhargava, Amit, Gonen, Mithat, Finn, Ronald, Scardino, Peter T, Fong, Yuman

“…Herpes simplex virus (HSV) oncolytic gene therapy is a promising treatment modality against cancer. We have demonstrated that androgen-induced cellular changes…”
Get full text

LuPARP: Phase 1 trial of 177Lu-PSMA-617 and olaparib in patients with metastatic castration resistant prostate cancer (mCRPC) by Sandhu, Shahneen, Joshua, Anthony M., Emmett, Louise, Crumbaker, Megan, Bressel, Mathias, Huynh, Rhonda, Banks, Patricia Diana, Wallace, Roslyn, Hamid, Anis, Inderjeeth, Andrisha Jade, Tran, Ben, Azad, Arun, Alipour, Ramin, Kong, Grace, Ravi Kumar, Aravind, Saghebi, Javad, Williams, Scott, Akhurst, Timothy J., Hicks, Rodney J., Hofman, Michael S

“…5005 Background: 177 Lu-PSMA-617, a PSMA-directed, radionuclide therapy improves progression free survival (PFS) and overall survival (OS) in patients (pts)…”
Get full text

Efficacy of systemic therapy following [ 177 Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) by Kostos, Louise Kathleen, Lai, William Yu Ching, Lambroglou, Peter, Medhurst, Elizabeth, Buteau, James Patrick, Sandhu, Shahneen, Tran, Ben, Spain, Lavinia Anne, Conduit, Ciara, Wallace, Roslyn, Alipour, Ramin, Akhurst, Timothy J., Kong, Grace, Cardin, Anthony, Saghebi, Javad, Ravi Kumar, Aravind, Hofman, Michael S, Azad, Arun

“…77 Background: [ 177 Lu]Lu-PSMA (LuPSMA) is currently FDA-approved for use in the post-taxane, post-antiandrogen setting in pts with mCRPC. Little is known…”
Get full text

PRINCE: Phase I trial of 177 Lu-PSMA-617 in combination with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC) by Sandhu, Shahneen, Joshua, Anthony M., Emmett, Louise, Spain, Lavinia Anne, Horvath, Lisa, Crumbaker, Megan, Anton, Angelyn, Wallace, Roslyn, Pasam, Anupama, Bressel, Mathias, Cassidy, Erin, Banks, Patricia, Dhiantravan, Nattakorn, Akhurst, Timothy J., Ravi Kumar, Aravind, Alipour, Ramin, Scalzo, Mark, Williams, Scott, Hicks, Rodney, Hofman, Michael S

“…5017 Background: The VISION and TheraP trials have established the safety and efficacy of 177 Lu-PSMA-617 in mCRPC with a 50% PSA response rate (PSA50-RR) of…”
Get full text